AML competition
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
- Posts: 128
- Joined: Tue Feb 23, 2016 5:48 pm
AML competition
Syros Pharmaceuticals (NASDAQ: SYRS) announced initial data from its Phase 2 SELECT-AML-1 trial evaluating tamibarotene with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression. The preliminary data resulted in a 100% CR/CRi rate in patients treated with tamibarotene, venetoclax, and azacitidine compared to 70% in patients randomized to treatment with venetoclax and azacitidine alone. Shares closed up 43% at $4.02.
-
- Posts: 1670
- Joined: Fri Jul 20, 2018 5:13 pm
Re: AML competition
Interesting, thanks for posting Jay.
-
- Posts: 54
- Joined: Wed Jul 13, 2016 4:15 pm
Re: AML competition
Hmmm wonder why this wasn't accepted for the ASH conf??